Peter Zuidewind

发表

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Approach to the management of paediatric HIV spontaneous controllers

S. Barnabas, A. V. van Rensburg, Peter Zuidewind, 2022, Southern African journal of infectious diseases.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS

C. Giaquinto, L. Kuhn, S. Barnabas, 2022, PloS one.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.

H. Zar, L. Wiesner, A. Van Rie, 2019, The Journal of antimicrobial chemotherapy.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age

M. Cotton, B. Laughton, S. Barnabas, 2021, AIDS.

Strong sex bias in elite control of paediatric HIV infection

C. Brander, P. Goulder, J. Ananworanich, 2018, AIDS.